U.S. Food & Drug Administration Approves Reata Pharmaceuticals’ SKYCLARYS™ for the Treatment of Adults and Adolescents Aged 16 Years and Older with Freidreich Ataxia

U.S. Food & Drug Administration Approves Reata Pharmaceuticals’ SKYCLARYS™ (Omaveloxolone) for the Treatment of Adults and Adolescents Aged 16 Years and Older with FA   Montreal,QC ., February 28, 2023 – This week  marks the approval of the first medication to treat Friedreich’s Ataxia (FA), a milestone for the FA...

Continue reading

Invitation to participate in a research project

Project title: The perspective of people who have recessive ataxia in assessing the impact of the disease: development of a self-reported assessment tool Responsible doctoral student: Marjolaine Tremblay, SW, Ph.D.(c) Supervision: Cynthia Gagnon, OT, Ph.D; Bernard Brais, MD, Ph.D. You are invited to participate in a research project to develop...

Continue reading